Metabolic Fatty Liver Disease

Current Knowledge, Therapeutic Treatments, and Future Directions

Erstverkaufstag: 01.07.2024

205,82 €*

Alle Preise inkl. MwSt.|Versandkostenfrei
ISBN-13:
9780323996495
Veröffentl:
2024
Erscheinungsdatum:
01.07.2024
Seiten:
300
Autor:
Linda Henry
Format:
234x191x0 mm
Sprache:
Deutsch
Beschreibung:

Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on metabolic fatty liver disease. The book extensively covers key areas in metabolic fatty liver disease research, including epidemiology (adults and children), economic burden, patient-reported outcome burden, natural history, current treatments, current diagnostic methods, controversies (NAFLD/MAFLD), current guidelines, fatty liver disease in the presence of other liver diseases as well as guidance on future research. This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes.
1. Global Epidemiology of NAFLD (now and forecasted)2. U.S. Epidemiology of NAFLD (now and forecasted). Linda Henry, PhD; Stanford University, USA3. Economic and patient reported outcome burden (now and forecasted)4. NAFLD pathogenesis (environmental and genetic)5. Clinical presentation and natural history.6. Non-liver comorbidities (prevalence and incidence)7. Screening, diagnosis, and evaluation of patients with NALFD8. Non-invasive evaluation of liver fibrosis (serum-based)9. Non-invasive evaluation of liver fibrosis (imaging/elastography-based)10. General treatment principles11. Non-surgical treatment of obesity and metabolic disease12. Endoscopic and surgical treatment of obesity13. Pharmacologic treatment of hepatic steatosis14. Overview and comparison of current guidelines (AASLD, EASL, APASL) on NAFLD and MAFLD controversies15. Special populations: Fatty liver disease in children and adolescent and in the presence of other liver diseases16. Special populations: Fatty liver disease in patients with chronic hepatitis

Kunden Rezensionen

Zu diesem Artikel ist noch keine Rezension vorhanden.
Helfen sie anderen Besuchern und verfassen Sie selbst eine Rezension.

Google Plus
Powered by Inooga